仙琚制药(002332) - 2016 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2016 was ¥522,304,171.39, a decrease of 7.00% compared to ¥561,637,464.43 in the same period last year[8]. - Net profit attributable to shareholders was ¥13,591,139.43, representing an increase of 15.87% from ¥11,729,974.54 year-on-year[8]. - The net profit after deducting non-recurring gains and losses was ¥11,786,026.47, up by 4.59% from ¥11,268,745.98 in the previous year[8]. - The net cash flow from operating activities improved significantly, with a net outflow of ¥40,825,550.34, a 58.49% reduction from a net outflow of ¥98,359,725.62 in the same period last year[8]. - The net profit attributable to shareholders for the first half of 2016 is expected to be between 50.87 million and 59.35 million RMB, representing a growth of 20.00% to 40.00% compared to 42.39 million RMB in the first half of 2015[23]. - The increase in net profit is primarily due to the continuous decline in raw material costs[23]. - The company anticipates a positive net profit for the first half of 2016, indicating no turnaround from a loss situation[23]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,378,704,307.94, down 1.75% from ¥3,438,943,218.46 at the end of the previous year[8]. - The net assets attributable to shareholders increased to ¥2,153,828,729.01, reflecting a growth of 0.64% from ¥2,140,207,332.50 at the end of the previous year[8]. - Long-term borrowings decreased by 73.79%, down 61.80 million CNY, mainly due to early repayment and reclassification of long-term debts[15]. - Other non-current assets decreased by 41.55%, down 2.73 million CNY, mainly due to reclassification to inventory materials[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 41,462[11]. - The largest shareholder, Xianju County State-owned Assets Investment Group, held 21.55% of the shares, totaling 131,658,869 shares[11]. - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[12]. Revenue and Expenses - Accounts receivable increased by 35.88%, up 144.37 million CNY, mainly due to seasonal industry impacts[15]. - Financial expenses decreased by 37.43%, down 5.72 million CNY, primarily due to reduced loan amounts and interest expenses[16]. - Investment income decreased by 123.53%, down 3.97 million CNY, mainly due to reduced profits from associated companies[16]. - Cash received from tax refunds decreased by 92.34%, down 1.82 million CNY, mainly due to reduced export tax rebates[17]. - Cash received from other operating activities decreased by 37.6%, down 4.60 million CNY, mainly due to reduced fiscal special funds[17]. - Tax expenses decreased by 54.85%, down 2.10 million CNY, mainly due to the reversal of previously accrued tax expenses[16]. Compliance and Regulations - The company has no violations regarding external guarantees during the reporting period[24]. - The company plans to adhere to relevant laws and regulations regarding the non-public issuance of shares, ensuring compliance with the agreements signed with investors[21]. - The company is focused on maintaining compliance with the Shenzhen Stock Exchange listing rules and other regulatory requirements[21]. - There are no non-operating fund occupations by controlling shareholders and their affiliates during the reporting period[25]. - The company did not engage in any research, communication, or interview activities during the reporting period[26]. Share Issuance - A total of 22,246,360 shares were subscribed by Huatai Pineapple- Xianju Pharmaceutical Private Placement Plan No. 45, and 5,055,991 shares by Huatai- Advantage Pharmaceutical Private Placement Plan No. 6[20]. - The company has issued a total of 20,223,964 new shares, which will also be subject to a 36-month transfer restriction[20]. - The company will not transfer the newly issued shares for a period of 36 months from the date of listing[20]. - The company has committed to fulfilling its obligations under the non-public issuance agreements signed with various investors[22].